The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | The value of CAR-T cell therapy in R/R DLBCL
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, briefly comments on the value of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), highlighting the results of the TRANSFORM (NCT03575351) and ZUMA-7 (NCT03391466) trials. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
